Literature DB >> 9738639

Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) guidelines.

J P Frolkis1, S J Zyzanski, J M Schwartz, P S Suhan.   

Abstract

BACKGROUND: We sought to determine the frequency with which physicians follow National Cholesterol Education Program (NCEP-ATPII) guidelines in screening for cardiovascular risk factors and treating hyperlipidemia. METHODS AND
RESULTS: We conducted a retrospective chart review on randomly sampled charts of 225 patients admitted to the coronary care unit between January and June 1996. The main outcome measures were rates of physician screening for coronary heart disease risk factors; rates of counseling for cigarette cessation, diet, and exercise; and extent of use of NCEP algorithms for obtaining LDL cholesterol values and treating hypercholesterolemia. Screening rates for interns (who performed best) were: cigarette use (89%), known coronary heart disease (74%), hypertension (68%), hyperlipidemia (59%), family history (56%), diabetes (37%), postmenopausal hormone therapy (11%), and premature menopause (1%). Four percent of smokers were counseled to quit, 14% of patients were referred to dietitians, and 1% were encouraged to exercise. A full lipid panel was obtained in 50% of patients in whom it was indicated on the basis of NCEP criteria. Patients were more likely to receive lipid-lowering treatment if NCEP criteria indicated that they should, but 36% of hospitalized patients and 46% of patients who should have been treated on discharge were not.
CONCLUSIONS: Physicians are poorly compliant with NCEP guidelines for risk factor assessment and counseling, even in patients at high risk for coronary heart disease. Physicians follow NCEP-ATPII algorithms for obtaining an LDL value, a key step in evaluating the need for treatment, only 50% of the time. NCEP criteria seem to influence the decision to initiate lipid-lowering therapy, but significant numbers of eligible patients remain untreated.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9738639     DOI: 10.1161/01.cir.98.9.851

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  17 in total

1.  Transitioning to a clinical practice model in your local environment.

Authors:  Timothy P Murphy; Gregory M Soares
Journal:  Semin Intervent Radiol       Date:  2005-03       Impact factor: 1.513

Review 2.  Health resource variability in the achievement of optimal performance and clinical outcome in ischemic heart disease.

Authors:  Partha Sardar; Amartya Kundu; Ramez Nairooz; Saurav Chatterjee; Gary S Ledley; Wilbert S Aronow
Journal:  Curr Cardiol Rep       Date:  2015-02       Impact factor: 2.931

3.  Undertreatment of hypercholesterolaemia: a population-based study.

Authors:  A K Mantel-Teeuwisse; W M M Verschuren; O H Klungel; D Kromhout; A D Lindemans; J Avorn; A J Porsius; A de Boer
Journal:  Br J Clin Pharmacol       Date:  2003-04       Impact factor: 4.335

4.  Development and validation of a model to project the long-term benefit and cost of alternative lipid-lowering strategies in patients with hypercholesterolaemia.

Authors:  John R Cook; Don Yin; Evo Alemao; Michael Drummond
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

5.  Current lipid management and low cholesterol goal attainment in common daily practice in Spain. The REALITY Study.

Authors:  F J García Ruiz; A Marín Ibáñez; F Pérez-Jiménez; X Pintó; G Nocea; C Ahumada; E Alemao; D Yin
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 6.  Population screening for hemochromatosis: has the time finally come?

Authors:  J C Barton; R T Acton
Journal:  Curr Gastroenterol Rep       Date:  2000-02

7.  Global risk assessment for lipid therapy to prevent coronary heart disease.

Authors:  C M Nass; S D Wiviott; J K Allen; W S Post; a R Blumenthal
Journal:  Curr Cardiol Rep       Date:  2000-09       Impact factor: 2.931

8.  Post-prandial lipid levels for assessing target goal achievement in type 2 diabetic patients taking statin.

Authors:  Mikyung Kim; Jihye Suk; Hyunjung Kim; Hyesuk Jung; Taeik Kim; Jeonghyun Park
Journal:  J Korean Med Sci       Date:  2010-02-17       Impact factor: 2.153

Review 9.  Strategies to increase HMG-CoA reductase inhibitor use after acute myocardial infarction.

Authors:  Joseph B Muhlestein
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

10.  The use of cholesterol-lowering medications after coronary revascularization.

Authors:  James M Brophy; Chantal Bourgault; Paul Brassard
Journal:  CMAJ       Date:  2003-11-25       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.